Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - imunološki za bovide - stoka (krave i junice) - za stada imunizacija zdravih krava i junica u mliječnih pasmina goveda s ponavljajući маститов problema, kako smanjiti učestalost субклинических маститов i učestalosti i težini kliničkih znakova kliničkog мастита uzrokovane zlatni staphylococcus, escherichia štapić i коагулазонегативные stafilokoki. cijela imunizacijska shema potiče imunitet od otprilike prvog dana nakon prve injekcije do približno 78 dana nakon treće injekcije (ekvivalent za 130 dana nakon poroda).

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - cjepiva - twinrix pedijatrijskih je indiciran za uporabu u sobe imunološki dojenčadi, djece i adolescenata od jedne godine do i uključujući 15 godina koji su u opasnosti od oba hepatitisa a i hepatitisa b infekcije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - influenza a virus/human strain: a/jena/vi5258/2009 (h1n1)pdm09, inactivated - imunološke, inaktivirane virusne vakcine za svinje, virus influence gripe - svinje - aktivna imunizacija svinja od dobi od 8 tjedana nadalje protiv pandemijskog virusa influence h1n1 svinjske gripe kako bi se smanjio virusni opterećenje pluća i virusni izlučivanje. the vaccine can be used during pregnancy up to three weeks before expected farrowing and during lactation lactation.

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

zoetis netherlands holdings b.v. podružnica zagreb za promidžbu, petra hektorovića 2, zagreb, hrvatska - inaktivirani herpesvirus goveda, tip 1 (bohv-1), soj difivac (ge negativan) - emulzija za injekciju - goveda

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunološke za suidae - svinja (za tov) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Europska Unija - hrvatski - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cjepiva - active immunisation against h5 subtype of influenza a virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - inaktiviran coxiella burnetii cjepivo, soj nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinantni verotoxin 2e e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svinje - aktivna imunizacija praščića od 2 dana starosti kako bi se spriječila smrtnost i smanjili klinički znakovi bolesti edema (uzrokovanog verotoksinom 2e koji proizvodi e. coli) i smanjiti gubitak dnevne debljanja tijekom završnog razdoblja u lice infekcija s verotoksinom 2e proizvodnjom e. coli do klanja od 164 dana starosti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - smanjenje neonatalne enterotoksikoze prasadi uzrokovano e. coli, koji eksprimiraju adhezinje f4ab, f4ac, f4ad, f5, f6 i f41 tijekom prvih dana života.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - svinjski circovirus tip 2 orf2 podjedinica antigena - immunologicals for suidae, inactivated viral vaccines - svinje - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.